VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]
For several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and mi...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2018-04-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/7-485/v1 |
_version_ | 1818994442673061888 |
---|---|
author | Helen A. Fletcher Mitali Chatterjee Andrea Cooper Tracy Hussell Paul M. Kaye Joann Prior Rajko Reljic Samantha Vermaak Martin Vordermeier Ann Williams Helen McShane |
author_facet | Helen A. Fletcher Mitali Chatterjee Andrea Cooper Tracy Hussell Paul M. Kaye Joann Prior Rajko Reljic Samantha Vermaak Martin Vordermeier Ann Williams Helen McShane |
author_sort | Helen A. Fletcher |
collection | DOAJ |
description | For several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and middle income countries. They are therefore often neglected due to the marginalisation of affected populations and the poor predicted commercial return on investment. Barriers to vaccine development include an incomplete understanding of protective immunity and translation from the bench into clinical vaccine trials. The current linear approach to vaccine research and development for these pathogens, which involves basic research, vaccine design, and vaccine evaluation in preclinical challenge models and clinical trials, is inefficient for these complex intracellular pathogens. We have established a Global Challenges Research Fund Network for VAccine deveLopment for complex Intracellular neglecteD pAThogEns, “VALIDATE”, where we aim to adopt a more flexible, integrated cross-pathogen approach to accelerate vaccine research and clinical development for these four pathogens, by cross-pathogen analyses, cross-discipline collaborations, and repeated integration of data from human and animal studies. This network provides a unique opportunity to bring together individuals working on four exemplar complex intracellular neglected pathogens (M.tb, Leishmania spp., B. pseudomallei and M.leprae), which share a common lifestyle as pathogens of macrophages, induce similar end-stage pathologies and alter host immune and metabolic responses. The horizontal collaborations established throughout this network, together with the provision of a protected environment for early data sharing, will exploit these biological synergies. By interrogating mechanisms that lead from infection to disease, we will be able to develop common vaccine development strategies for these and other complex intracellular pathogens. |
first_indexed | 2024-12-20T20:58:01Z |
format | Article |
id | doaj.art-81e9dccdef394b8ea1d7097182dc19a6 |
institution | Directory Open Access Journal |
issn | 2046-1402 |
language | English |
last_indexed | 2024-12-20T20:58:01Z |
publishDate | 2018-04-01 |
publisher | F1000 Research Ltd |
record_format | Article |
series | F1000Research |
spelling | doaj.art-81e9dccdef394b8ea1d7097182dc19a62022-12-21T19:26:47ZengF1000 Research LtdF1000Research2046-14022018-04-01710.12688/f1000research.14386.115655VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved]Helen A. Fletcher0Mitali Chatterjee1Andrea Cooper2Tracy Hussell3Paul M. Kaye4Joann Prior5Rajko Reljic6Samantha Vermaak7Martin Vordermeier8Ann Williams9Helen McShane10The London School of Hygiene and Tropical Medicine, London, UKDepartment of Pharmacology, Institute of Postgraduate Medical Education & Research, Kolkata, IndiaDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, UKManchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UKCentre for Immunology and Infection, University of York, York, UKDefence Science and Technology Laboratory, Porton Down, UKInstitute for Infection and Immunity, St George's University of London, London, UKThe Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UKDepartment of Bacteriology, Animal and Plant Health Agency, Weybridge, UKNational Infection Service, Public Health England, Porton Down, UKThe Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UKFor several complex intracellular pathogens, we have an urgent need for effective vaccines and yet there are common barriers to vaccine development. These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis, cause a huge burden of disease and disproportionately affect low and middle income countries. They are therefore often neglected due to the marginalisation of affected populations and the poor predicted commercial return on investment. Barriers to vaccine development include an incomplete understanding of protective immunity and translation from the bench into clinical vaccine trials. The current linear approach to vaccine research and development for these pathogens, which involves basic research, vaccine design, and vaccine evaluation in preclinical challenge models and clinical trials, is inefficient for these complex intracellular pathogens. We have established a Global Challenges Research Fund Network for VAccine deveLopment for complex Intracellular neglecteD pAThogEns, “VALIDATE”, where we aim to adopt a more flexible, integrated cross-pathogen approach to accelerate vaccine research and clinical development for these four pathogens, by cross-pathogen analyses, cross-discipline collaborations, and repeated integration of data from human and animal studies. This network provides a unique opportunity to bring together individuals working on four exemplar complex intracellular neglected pathogens (M.tb, Leishmania spp., B. pseudomallei and M.leprae), which share a common lifestyle as pathogens of macrophages, induce similar end-stage pathologies and alter host immune and metabolic responses. The horizontal collaborations established throughout this network, together with the provision of a protected environment for early data sharing, will exploit these biological synergies. By interrogating mechanisms that lead from infection to disease, we will be able to develop common vaccine development strategies for these and other complex intracellular pathogens.https://f1000research.com/articles/7-485/v1 |
spellingShingle | Helen A. Fletcher Mitali Chatterjee Andrea Cooper Tracy Hussell Paul M. Kaye Joann Prior Rajko Reljic Samantha Vermaak Martin Vordermeier Ann Williams Helen McShane VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved] F1000Research |
title | VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved] |
title_full | VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved] |
title_fullStr | VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved] |
title_full_unstemmed | VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved] |
title_short | VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy [version 1; referees: 2 approved] |
title_sort | validate exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis leishmaniasis melioidosis and leprosy version 1 referees 2 approved |
url | https://f1000research.com/articles/7-485/v1 |
work_keys_str_mv | AT helenafletcher validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT mitalichatterjee validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT andreacooper validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT tracyhussell validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT paulmkaye validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT joannprior validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT rajkoreljic validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT samanthavermaak validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT martinvordermeier validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT annwilliams validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved AT helenmcshane validateexploitingthesynergybetweencomplexintracellularpathogenstoexpeditevaccineresearchanddevelopmentfortuberculosisleishmaniasismelioidosisandleprosyversion1referees2approved |